William Carter

William A. Carter, MD, is the inventor of Ampligen, short for “AMPLIfied GENetic activity,” a drug being tested for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Dr. Carter was a researcher at John Hopkins University and Hahnemann University in the 1970's, where he was able to modify a potential cancer drug to reduce its toxicity, thus creating Ampligen. Dr. Carter obtained the license for Ampligen from John Hopkins University and affiliated with the small company, Hemispherx, now called Hemispherx Biopharma in 1978 to manufacture it.

Once the long-time CEO and Chairman of the Board of Directors for Hemispherx Biopharma, he was terminated from his position in January 2016 as the result of a "strong financial austerity plan."

Notable studies

 * 1994, A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome
 * 2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
 * 2015, Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity
 * 2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod.